About Delmar pharmaceuticals
Delmar Pharmaceuticals: Revolutionizing Cancer Treatment with Innovative Therapies
Delmar Pharmaceuticals is a leading biopharmaceutical company that specializes in developing innovative cancer therapies. The company's mission is to provide patients with new treatment options in areas where they have failed or become intolerable to currently available treatments. Delmar Pharmaceuticals has a strong commitment to research and development, and its team of experts works tirelessly to discover new ways of treating cancer.
The company's flagship product, VAL-083, is a first-in-class small molecule chemotherapy drug that has shown promising results in the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer. VAL-083 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of GBM, which means it will receive expedited review and approval processes.
Delmar Pharmaceuticals' pipeline also includes other promising therapies for various types of cancers such as ovarian cancer, non-small cell lung cancer (NSCLC), and pediatric brain tumors. The company's innovative approach to developing these therapies involves targeting specific molecular pathways that are involved in tumor growth and progression.
One example is Delmar Pharmaceutical's lead candidate for ovarian cancer therapy - Eniluracil + 5-FU (5-fluorouracil). This combination therapy targets thymidylate synthase (TS), an enzyme essential for DNA synthesis required by rapidly dividing cells such as those found in tumors. By inhibiting TS activity, Eniluracil + 5-FU can effectively kill tumor cells while sparing normal cells from damage.
Another exciting development from Delmar Pharmaceuticals' pipeline is its NSCLC therapy candidate - DM-CHOC-PEN. This novel drug combines two potent chemotherapeutic agents - temozolomide and chloroquine - into one formulation that can penetrate the blood-brain barrier more efficiently than either drug alone. DM-CHOC-PEN has shown promising results in preclinical studies and is currently undergoing clinical trials.
Delmar Pharmaceuticals' commitment to innovation extends beyond its drug development programs. The company also invests heavily in research collaborations with leading academic institutions and industry partners to advance the understanding of cancer biology and identify new therapeutic targets.
In conclusion, Delmar Pharmaceuticals is a pioneering biopharmaceutical company that is revolutionizing cancer treatment with innovative therapies. Its commitment to research and development, combined with its expertise in targeting specific molecular pathways involved in tumor growth, has led to the discovery of promising new treatments for various types of cancers. With its flagship product VAL-083 already granted orphan drug designation by the FDA, Delmar Pharmaceuticals is poised to make a significant impact on the field of oncology and improve patient outcomes worldwide.